BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 19704167)

  • 1. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
    Pollicino T; Isgrò G; Di Stefano R; Ferraro D; Maimone S; Brancatelli S; Squadrito G; Di Marco V; Craxì A; Raimondo G
    Antivir Ther; 2009; 14(5):649-54. PubMed ID: 19704167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
    J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
    Selabe SG; Song E; Burnett RJ; Mphahlele MJ
    J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C.
    Hsieh TH; Tseng TC; Liu CJ; Lai MY; Chen PJ; Hsieh HL; Chen DS; Kao JH
    Antivir Ther; 2009; 14(8):1157-63. PubMed ID: 20032545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
    Jardi R; Rodriguez-Frias F; Schaper M; Ruiz G; Elefsiniotis I; Esteban R; Buti M
    J Viral Hepat; 2007 Dec; 14(12):835-40. PubMed ID: 18070286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.
    Fukai K; Zhang KY; Imazeki F; Kurihara T; Mikata R; Yokosuka O
    J Viral Hepat; 2007 Sep; 14(9):661-6. PubMed ID: 17697019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
    Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
    AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B.
    Ogata N; Fujii K; Takigawa S; Nomoto M; Ichida T; Asakura H
    J Med Virol; 1999 Nov; 59(3):270-6. PubMed ID: 10502255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Chan HL; Wang H; Niu J; Chim AM; Sung JJ
    Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis and recombinant construction of HBV the reverse transcriptase gene with drug-resistant mutations from 40 patients with chronic hepatitis B].
    Su HL; Liu Y; Liu W; Zhong YW; Chen XY; Wang CM; Liu YM; Xu DP
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):340-2. PubMed ID: 20387480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.